Trial Now Recruiting: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (NCT05868629)

WHY IT MATTERS

If you have a rare solid tumor with a BRAF V600E mutation and your doctor has already recommended dabrafenib plus trametinib treatment, this trial offers an opportunity to participate in research that could help future patients while receiving the same treatment your doctor planned for you anyway.

Researchers are testing a combination of two cancer drugs called dabrafenib and trametinib in patients with rare tumors that have a specific genetic change called BRAF V600E. This is a phase IV study, which means the drugs have already been approved and doctors are gathering more information about how well they work. The study will include children (age 1 and up) and adults, and is currently looking for 40 patients to participate.

NCT ID: NCT05868629 Status: RECRUITING Conditions: Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors Enrollment: 40 Sponsor: Novartis Pharmaceuticals Summary: This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation.

YOU CAN ACT ON THIS

If you have a BRAF V600E mutation-positive unresectable or metastatic solid tumor and your doctor has recommended this drug combination, contact the trial site now to ask if you're eligible—enrollment is actively recruiting.